- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03992664
Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. (EGFR)
Effectiveness of Educational Intervention for Patients That Receive Treatment With EGFRI
The main adverse reaction of EGFR seen in patients is rash. EGFR treated patients have a 24-95% incidence of rash depending on the type of treatment they receive. Skin toxicity may occur in more than 80% of patients treated with cetuximab.
If a severe rash (Grade 3 or 4) occurs, a dose reduction or discontinuation of treatment may be required. Also, infections are the main secondary side effect caused by the rash.
The aim of the study is through a randomized clinical trial feasibility study to investigate the effectiveness of an educational intervention in patients receiving EGFRI therapy.
It will be randomly selected which patients will belong to the intervention group and who in the control group. The type of program involves educational intervention.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
In recent years, EGFRI (Epidermal Growth Factor Receptor Inhibitor) have evolved as effective anti-cancer drugs. They are distinguished in monoclonal antibodies (cetuximab and panitumumab) and EGFR (TKIs) kinase inhibitors gefitinib, erlotinib and lapatinib, where they are used in the treatment of colon, rectal, head and neck, lung, pancreas and of breast.
According to studies, the usual treatment for the prevention and treatment of skin rash refers to the use of antibiotics such as doxycycline, tetracycline and cortisone products such as hydrocortisone. It is also recommended to use moisturizing cream.
The study of Carmine P. et al., 2011 mentions the need to investigate educational measures for the rash due to EGFR treatment.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Athienou
-
Larnaca, Athienou, Cypern, 7600
- Eleni Papoui
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients who take EGFR therapy for the first time.
- Classify at 0 or 1 according to WHO performance status.
Exclusion Criteria:
- Patients with previous exposure to EGFR treatment.
- People already suffering from rash.
- People already suffering with other dermatological problems, eg psoriasis.
- People already taking part in any other study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: EDUCATION
If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
|
The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects. The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks.
Andre navne:
|
Ingen indgriben: NON-INTERVENTION
The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.
Tidsramme: 4 weeks
|
Identify the degree of rash using the NCI-CTCAE criteria.
the degree of rash will compare in the experimental group (education) and in the non-experimental group (no education).
|
4 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Evaluation of the quality of life of all patients through the SF 36 questionnaire
Tidsramme: 4 weeks
|
The SF 36 questionnaire will be given to every patient from the first time of the meeting.
The questionnaire will be given every week.
|
4 weeks
|
Assessing the quality of life in relation to the rash through the QLQI questionnaire.
Tidsramme: 3 weeks
|
The QLQI questionnaire will be given in every patient from the second meeting because the questionnaire concerns questions about last week.
|
3 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: ANDREAS CHARALAMBOUS, PhD, Cyprus University of Technology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 0000-0001-5580-7256
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien
Kliniske forsøg med EDUCATION
-
Tokat Gaziosmanpasa UniversityAfsluttetStigmatisering | Funktionalitet | Peer Support | Kroniske psykiske lidelser | Træning i psykosociale færdigheder | IndsigtKalkun
-
Thomas Jefferson UniversityRekrutteringProstata karcinomForenede Stater
-
Universidade Federal de Sao CarlosAfsluttet
-
Thomas Jefferson UniversityAfsluttetHæmatopoietisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForenede Stater
-
Rutgers, The State University of New JerseyRekrutteringMiljøeksponering | Udvalg af madForenede Stater
-
University of Nevada, Las VegasSt. Ambrose UniversityAfsluttetLændesmerter | Smerte, kronisk | Smerter, RygForenede Stater
-
The University of Texas at ArlingtonUniversity of Texas Southwestern Medical CenterAfsluttet
-
Bilecik Seyh Edebali UniversitesiAfsluttetBrug af Flipped Classroom Model med sygeplejestuderendeKalkun
-
Centers for Disease Control and PreventionAfsluttetHIV-infektioner | Hepatitis CForenede Stater
-
Vrije Universiteit BrusselUniversiteit AntwerpenAfsluttetSmerte | Barn | Undersøgelser og spørgeskemaer | Viden | ValideringBelgien